Remove company gilead-sciences
article thumbnail

Patients Look Beyond the Pandemic to Pharma for Engagement, Innovation, and Integrity

Health Populi

Compared with a year ago, more patients and their advocates are seeking quality therapies, innovation, engagement, and integrity from pharmaceutical companies, based on research published today from PatientView. Gilead Science, and. Generics such as Mylan and Teva, among others. Roche/Genentech.

BioTech 389
article thumbnail

Data privacy, lack of in-person contact among major barriers to telehealth uptake among Asian PLHIV

Healthcare IT News - Telehealth

This report followed another Gilead-backed study in 2020 which found that over half of PLHIVs and 64% of at-risk individuals in APAC have no access to telehealth services.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmaceutical Multinationals Continue To Spurn The Opportunity To Connect Via Social Media At A Local Level

Digital Health Global

The Report shows that the world’s leading pharmaceutical companies continue to spurn the opportunity to connect via social media at a local level. The pandemic and other crises have raised expectations that companies should be more purpose-driven. All companies in the study have ‘international apps’. Novartis 2.

article thumbnail

Moderna, one of the biggest gambles in Biotech history to be tested on Wall Street with $10Bn IPO

Lloyd Price

That figure is subject to change as the company gets closer to its debut. But the method is largely unproven in humans, and Moderna isn’t the only company working on it—others like CureVac, Translate Bio (NASDAQ: TBIO), and BioNTech are as well. Kim said at the time that Moderna aims to become a company worth more than $50 billion.

BioTech 52
article thumbnail

Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback?

Insulin Nation

Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year, reveals a new database logging 12,000 donations from large publicly traded drugmakers to such organizations. Unlike payments to doctors and lobbying expenses, companies do not have to report payments to the groups.